Next 10 |
home / stock / janx / janx articles
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...
Janux Therapeutics Inc (NASDAQ:JANX) shares are trading higher following Wednesday’s reports suggesting the company is considering a pos...
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose shar...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to ...
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Helix Energy posted ...
On Monday, Janux Therapeutics Inc (NASDAQ:JANX) released updated data for its JANX007 in metastatic castration-resistant prostate cancer ...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,915...
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) ...
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow...
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
2024-05-13 10:30:04 ET Wedbush analyst issues BUY recommendation for JANX on May 13, 2024 09:00AM ET. The previous analyst recommendation was Buy. JANX was trading at $49.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $651.8 million in cash and cash equivalents and short-term...
2024-04-30 00:06:00 ET Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.4...